Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States

Published:November 29, 2022DOI:


      Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is an X-linked condition caused by pathogenic variants in the iduronate-2-sulfatase gene. The resulting reduced activity of the enzyme iduronate-2-sulfatase leads to accumulation of glycosaminoglycans that can progressively affect multiple organ systems and impair neurologic development. In 2006, the US Food and Drug Administration approved idursulfase for intravenous enzyme replacement therapy for MPS II. After the data suggesting that early treatment is beneficial became available, 2 states, Illinois and Missouri, implemented MPS II newborn screening. Following a recommendation of the Advisory Committee on Heritable Disorders in Newborns and Children in February 2022, in August 2022, the US Secretary of Health and Human Services added MPS II to the Recommended Uniform Screening Panel, a list of conditions recommended for newborn screening. MPS II was added to the Recommended Uniform Screening Panel after a systematic evidence review reported the accuracy of screening, the benefit of presymptomatic treatment compared with usual case detection, and the feasibility of implementing MPS II newborn screening. This manuscript summarizes the findings of the evidence review that informed the Advisory Committee’s decision.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      ACMG Member Login

      Are you an ACMG Member? Sign in for online access.


      Subscribe to Genetics in Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kemper A.
        • Lam K.K.
        • Letostak T.
        • et al.
        Evidence-based review of newborn screening for mucopolysaccharidosis type II: final report. Health Resources and Services Administration.
        (Published February 20, 2022)
        • Sukegawa K.
        • Matsuzaki T.
        • Fukuda S.
        • et al.
        Brother/sister siblings affected with Hunter disease: evidence for skewed X chromosome inactivation.
        Clin Genet. 1998; 53: 96-101
        • Çelik B.
        • Tomatsu S.C.
        • Tomatsu S.
        • Khan S.A.
        Epidemiology of mucopolysaccharidoses update.
        Diagnostics (Basel). 2021; 11: 273
        • Puckett Y.
        • Mallorga-Hernández A.
        • Montaño A.M.
        Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities.
        Orphanet J Rare Dis. 2021; 16: 241
        • Bilyeu H.
        • Washburn J.
        • Vermette L.
        • Klug T.
        Validation and implementation of a highly sensitive and efficient newborn screening assay for mucopolysaccharidosis type II.
        Int J Neonatal Screen. 2020; 6: 79
        • Burton B.K.
        • Hickey R.
        • Hitchins L.
        Newborn screening for mucopolysaccharidosis type II in Illinois: an update.
        Int J Neonatal Screen. 2020; 6: 73
        • Lau H.A.
        • Harmatz P.
        • Botha J.
        Clinical characteristics of patients with neuronopathic and non-neuronopathic mucopolysaccharidosis type II: data from the Hunter Outcome Survey.
        Mol Genet Metab. 2019; 126: S91
        • Josahkian J.A.
        • Brusius-Facchin A.C.
        • Netto A.B.O.
        • et al.
        Genotype-phenotype studies in a large cohort of Brazilian patients with Hunter syndrome.
        Am J Med Genet C Semin Med Genet. 2021; 187 (Published correction appears in Am J Med Genet C Semin Med Genet. 2022;190(3):405-406. 349-356
        • Burton B.K.
        • Jego V.
        • Mikl J.
        • Jones S.A.
        Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).
        J Inherit Metab Dis. 2017; 40: 867-874
        • Muenzer J.
        • Gucsavas-Calikoglu M.
        • McCandless S.E.
        • Schuetz T.J.
        • Kimura A.
        A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
        Mol Genet Metab. 2007; 90: 329-337
        • Muenzer J.
        • Wraith J.E.
        • Beck M.
        • et al.
        A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).
        Genet Med. 2006; 8 (Published correction appears in Genet Med. 2006;8(9):599. 465-473
        • Giugliani R.
        • Harmatz P.
        • Jones S.A.
        • et al.
        Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients.
        Mol Genet Metab Rep. 2017; 12: 2-7
        • Pano A.
        • Barbier A.J.
        • Bielefeld B.
        • Whiteman D.A.
        • Amato D.A.
        Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).
        Orphanet J Rare Dis. 2015; 10: 50
        • McBride K.L.
        • Berry S.A.
        • Braverman N.
        • ACMG Therapeutics Committee
        Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG).
        Genet Med. 2020; 22: 1735-1742
        • Pollard L.M.
        • Jones J.R.
        • Wood T.C.
        Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations.
        J Inherit Metab Dis. 2013; 36: 179-187
        • Stapleton M.
        • Kubaski F.
        • Mason R.W.
        • et al.
        Presentation and treatments for mucopolysaccharidosis type II (MPS II; Hunter syndrome).
        Expert Opin Orphan Drugs. 2017; 5: 295-307
        • Araya K.
        • Sakai N.
        • Mohri I.
        • et al.
        Localized donor cells in brain of a Hunter disease patient after cord blood stem cell transplantation.
        Mol Genet Metab. 2009; 98: 255-263
        • Taylor M.
        • Khan S.
        • Stapleton M.
        • et al.
        Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future.
        Biol Blood Marrow Transplant. 2019; 25: e226-e246
        • Tanaka A.
        • Okuyama T.
        • Suzuki Y.
        • et al.
        Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan.
        Mol Genet Metab. 2012; 107: 513-520
        • Kubaski F.
        • Yabe H.
        • Suzuki Y.
        • et al.
        Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II.
        Biol Blood Marrow Transplant. 2017; 23: 1795-1803
        • Guffon N.
        • Bertrand Y.
        • Forest I.
        • Fouilhoux A.
        • Froissart R.
        Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years.
        J Pediatr. 2009; 154: 733-737
        • McKinnis E.J.
        • Sulzbacher S.
        • Rutledge J.C.
        • Sanders J.
        • Scott C.R.
        Bone marrow transplantation in Hunter syndrome.
        J Pediatr. 1996; 129: 145-148
        • Vellodi A.
        • Young E.
        • Cooper A.
        • Lidchi V.
        • Winchester B.
        • Wraith J.E.
        Long-term follow-up following bone marrow transplantation for Hunter disease.
        J Inherit Metab Dis. 1999; 22: 638-648
        • Patel P.
        • Suzuki Y.
        • Tanaka A.
        • et al.
        Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter syndrome.
        Mol Genet Metab Rep. 2014; 1: 184-196
        • Tanjuakio J.
        • Suzuki Y.
        • Patel P.
        • et al.
        Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation.
        Mol Genet Metab. 2015; 114: 161-169
        • Wang D.
        • Wood T.
        • Sadilek M.
        • Scott C.R.
        • Turecek F.
        • Gelb M.H.
        Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease).
        Clin Chem. 2007; 53: 137-140
        • Ruijter G.J.
        • Goudriaan D.A.
        • Boer A.M.
        • et al.
        Newborn screening for Hunter disease: a small-scale feasibility study.
        JIMD Rep. 2014; 14: 23-27
        • Lampe C.
        • Atherton A.
        • Burton B.K.
        • et al.
        Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age.
        JIMD Rep. 2014; 14: 99-113
        • Tajima G.
        • Sakura N.
        • Kosuga M.
        • Okuyama T.
        • Kobayashi M.
        Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings.
        Mol Genet Metab. 2013; 108: 172-177
        • Tylki-Szymanska A.
        • Jurecka A.
        • Zuber Z.
        • Rozdzynska A.
        • Marucha J.
        • Czartoryska B.
        Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up.
        Acta Paediatr. 2012; 101: e42-e47
        • Tomita K.
        • Okamoto S.
        • Seto T.
        • et al.
        Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report.
        JIMD Rep. 2021; 62: 9-14
        • Grant N.
        • Sohn Y.B.
        • Ellinwood N.M.
        • et al.
        Timing is everything: clinical courses of Hunter syndrome associated with age at initiation of therapy in a sibling pair.
        Mol Genet Metab Rep. 2022; 30100845
        • Muenzer J.
        • Botha J.
        • Harmatz P.
        • Giugliani R.
        • Kampmann C.
        • Burton B.K.
        Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).
        Orphanet J Rare Dis. 2021; 16: 456
        • Kemper A.R.
        • Boyle C.A.
        • Aceves J.
        • et al.
        Long-term follow-up after diagnosis resulting from newborn screening: statement of the US Secretary of Health and Human Services’ Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children.
        Genet Med. 2008; 10 (Published correction appears in Genet Med. 2008;10(5):368. 259-261
        • Hinton C.F.
        • Feuchtbaum L.
        • Kus C.A.
        • et al.
        What questions should newborn screening long-term follow-up be able to answer? A statement of the US Secretary for Health and Human Services’ Advisory Committee on Heritable Disorders in Newborns and Children.
        Genet Med. 2011; 13: 861-865
        • Kemper A.R.
        • Grosse S.D.
        • Baker M.
        • Pollock A.J.
        • Hinton C.F.
        • Shapira S.K.
        Treatment discontinuation by 3 years after levothyroxine initiation among children diagnosed with congenital hypothyroidism.
        J Pediatr. 2020; 223: 136-140
        • Kemper A.R.
        • Boyle C.A.
        • Brosco J.P.
        • Grosse S.D.
        Ensuring the life-span benefits of newborn screening.
        Pediatrics. 2019; 144e20190904